A Study of an Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older

A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Immunogenicity and Safety of Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older

The purpose of this study is to evaluate the immunogenicity and safety of Ad26.RSV.preF-based vaccine and quadrivalent high-dose seasonal influenza vaccine when administered either concomitantly or separately.

Study Overview

• Status: Completed
• Conditions: Influenza, Human Prevention; Respiratory Syncytial Viruses Prevention
• Intervention / Treatment: Biological: Ad26.RSV.preF-based vaccine; Biological: Quadrivalent High-dose Influenza Vaccine; Biological: Placebo

• Study Type: Interventional
• Enrollment (Actual): 777
• Phase: Phase 3

Contacts and Locations

Study Locations

• United States
  • California
    • Long Beach, California, United States, 90806
      • Ark Clinical Research
  • Florida
    • Hollywood, Florida, United States, 33024
      • Research Centers of America, LLC
    • Port Orange, Florida, United States, 32127
      • Progressive Medical Research
    • The Villages, Florida, United States, 32162
      • Synexus Clinical Research US Inc
  • Illinois
    • Chicago, Illinois, United States, 60602
      • Synexus Clinical Research US Inc
  • Maryland
    • Rockville, Maryland, United States, 20854
      • Meridian Clinical Research, LLC
  • Missouri
    • Saint Louis, Missouri, United States, 63141
      • Sundance Clinical Research
    • Saint Louis, Missouri, United States, 63141
      • Synexus Clinical Research US Inc
  • Nebraska
    • Grand Island, Nebraska, United States, 68803
      • Meridian Clinical Research, LLC
    • Lincoln, Nebraska, United States, 68510
      • Meridian Clinical Research, LLC
    • Norfolk, Nebraska, United States, 68701
      • Meridian Clinical Research, LLC
    • Omaha, Nebraska, United States, 68134
      • Meridian Clinical Research, LLC
  • Oklahoma
    • Yukon, Oklahoma, United States, 73099
      • Tekton Research Inc.
  • South Carolina
    • North Charleston, South Carolina, United States, 29405
      • Coastal Carolina Research Center
    • Spartanburg, South Carolina, United States, 29303
      • VitaLink Research Spartanburg
  • Tennessee
    • Knoxville, Tennessee, United States, 37920
      • AMR New Orleans, Formerly New Orleans Center for Clinical Research - New Orleans, an AMR company
  • Texas
    • Austin, Texas, United States, 78705
      • Optimal Research
    • Austin, Texas, United States, 78745
      • Tekton Research Inc.
    • Tomball, Texas, United States, 77375
      • DM Clinical Research

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 65 years and older (Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Willing and able to adhere to the prohibitions and restrictions specified in this protocol
• In the investigator's clinical judgment, the participant must be in stable health at the time of vaccination. Participants will be included on the basis of medical history and vital signs performed between informed consent from (ICF) signature and vaccination
• Before randomization, a participant must be not intending to conceive by any methods, postmenopausal or surgically sterile
• From the time of vaccination through 3 months after vaccination, agrees not to donate blood
• Must be willing to provide verifiable identification, have means to be contacted and to contact the investigator during the study
• Participant must be able to work with smartphones/tablets/computers

Exclusion Criteria:

• History of malignancy within 5 years before screening not in the following categories: a) participants with squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix may be enrolled at the discretion of the investigator; b) participants with a history of malignancy within 5 years before screening, with minimal risk of recurrence per investigator's judgement, can be enrolled
• Known or suspected allergy or history of anaphylaxis or other serious adverse reactions to vaccines or their excipients (including specifically the excipients of the study vaccine)
• History of severe allergic reactions (example, anaphylaxis) to any component of the Quadrivalent high-dose influenza vaccine, including egg protein, or following a previous dose of any influenza vaccine
• Has abnormal function of the immune system resulting from either clinical condition, chronic or recurrent use of systemic corticosteroids within 2 months prior to study vaccination, or immunomodulating agents within 6 months prior to study vaccination
• Per medical history, participant has chronic active hepatitis B or hepatitis C infection
• History of acute polyneuropathy (example, Guillain-Barre syndrome) or chronic idiopathic demyelinating polyneuropathy
• Has a serious chronic disorder, example, chronic obstructive pulmonary disease or congestive heart failure, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, Alzheimer's disease, or has any condition, including conditions placing the participant at high risk for severe influenza, for which, in the opinion of the investigator, participation would not be in the best interest of the participant or that could prevent, limit, or confound the protocol-specified assessments
• Received vaccination with seasonal influenza vaccine for the current influenza season in the Northern Hemisphere

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Group 1: Coadministration (CoAd) Group; Participants will receive Ad26.RSV.preF-based vaccine and quadrivalent high dose influenza vaccine concomitantly on Day 1 and placebo on Day 29.	Biological: Ad26.RSV.preF-based vaccine; Ad26.RSV.preF-based vaccine will be administered as single IM injection.; Biological: Quadrivalent High-dose Influenza Vaccine; Quadrivalent High-dose Influenza Vaccine will be administered as IM injection.; Biological: Placebo; Placebo will be administered as IM injection to Ad26.RSV.preF-based vaccine.
Experimental: Group 2: Control Group; Participants will receive placebo and quadrivalent high-dose influenza vaccine on Day 1 and Ad26.RSV.preF-based vaccine on Day 29.	Biological: Ad26.RSV.preF-based vaccine; Ad26.RSV.preF-based vaccine will be administered as single IM injection.; Biological: Quadrivalent High-dose Influenza Vaccine; Quadrivalent High-dose Influenza Vaccine will be administered as IM injection.; Biological: Placebo; Placebo will be administered as IM injection to Ad26.RSV.preF-based vaccine.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Geometric Mean Titers (GMTs) of Hemagglutination Inhibition (HI) Antibodies Against Each of the Four Influenza Vaccine Strains as Measured by HI Assay	Hemagglutination is a phenomenon by which the hemagglutinin protein of influenza viruses can bind to sialic acid receptors on the red blood cell membrane, thereby forming clumps and is the basis for the HI assay. GMTs of HI antibodies against each of the four influenza vaccine strains as measured by HI assay at 28 days after the administration of a quadrivalent high-dose seasonal influenza vaccine (fluzone) were reported. The analysis was performed on 2 influenza A strains [A/Victoria and A/Tasmania] and 2 influenza B strains [B/Washington and B/Phuket]).	28 days after vaccination with Fluzone on Day 1 (Day 29)
GMTs of Prefusion F-protein (preF) Antibodies as Assessed by Enzyme-linked Immunosorbent Assay (ELISA) on Day 29	GMTs of preF antibodies at 28 days after the administration of Ad26.RSV.preF-based vaccine as assessed by ELISA on Day 29 were reported. This outcome measure was planned to be analyzed for specified arm only.	28 days after vaccination with Ad26.RSV.preF-based vaccine on Day 1 (Day 29)
GMTs of PreF Antibodies as Assessed by Enzyme-linked Immunosorbent Assay (ELISA) on Day 57	GMTs of preF antibodies at 28 days after the administration of Ad26.RSV.preF-based vaccine as assessed by ELISA on Day 57 were reported. This outcome measure was planned to be analyzed for specified arm only.	28 days after vaccination with Ad26.RSV.preF-based vaccine on Day 29 (Day 57)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants With Solicited Local Adverse Events (AEs) After Study Vaccination 1	Number of participants with solicited local AEs after study vaccination 1 were reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Solicited local AEs that included injection site pain/tenderness, erythema and swelling at the study vaccine injection site, were used to assess the reactogenicity of the study vaccine and were pre-defined local (injection site). Solicited local AEs were reported separately for all vaccines because fluzone and RSV vaccine mixture (containing both Ad26. RSV. preF 1*10^11 vp and RSV preF protein 150 mcg) in group 1 were administered in opposite arms on Day 1. Similarly, fluzone and placebo in group 2 were administered in opposite arms on Day 1. Hence, the data for this outcome measure was analyzed separately for each vaccine.	Up to 7 days after study vaccination 1 on Day 1 (Day 8)
Number of Participants With Solicited Local AEs After Study Vaccination 2	Number of participants with solicited local AEs after study vaccination 2 were reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Solicited local AEs that included injection site pain/tenderness, erythema and swelling at the study vaccine injection site, were used to assess the reactogenicity of the study vaccine and were pre-defined local (injection site).	Up to 7 days after study vaccination 2 on Day 29 (Day 36)
Number of Participants With Solicited Systemic AEs After Study Vaccination 1	Number of participants with solicited systemic AEs after study vaccination 1 were reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Solicited systemic events included events such as fatigue, headache, nausea, and myalgia, for which participants were specifically questioned and which were noted by participants in their participant diary for 7 days post vaccination (day of vaccination and the subsequent 7 days).	Up to 7 days after study vaccination 1 on Day 1 (Day 8)
Number of Participants With Solicited Systemic AEs After Study Vaccination 2	Number of participants with solicited systemic AEs after study vaccination 2 were reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Systemic events included events such as fatigue, headache, nausea, and myalgia, for which participants will be specifically questioned and which will be noted by participants in their participant diary for 7 days post vaccination (day of vaccination and the subsequent 7 days).	Up to 7 days after study vaccination 2 on Day 29 (Day 36)
Number of Participants With Unsolicited AEs After Study Vaccination 1	Number of participants with unsolicited AEs after study vaccination 1 were reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Unsolicited AEs were all AEs for which the participant was not specifically questioned in the participant diary.	Up to 28 days after study vaccination 1 on Day 1 (Day 29)
Number of Participants With Unsolicited AEs After Study Vaccination 2	Number of participants with unsolicited AEs after study vaccination 2 were reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Unsolicited AEs were all AEs for which the participant was not specifically questioned in the participant diary.	Up to 28 days after study vaccination 2 on Day 29 (Day 57)
Number of Participants With Serious Adverse Events (SAEs) Up to Study Vaccination 1	Number of participants with SAEs up to study vaccination 1 were reported. SAE is any untoward medical occurrence that at any dose may result in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product.	From Day 1 up to Day 29
Number of Participants With Serious Adverse Events (SAEs) Up to Study Vaccination 2	Number of participants with SAEs up to study vaccination 2 were reported. SAE is any untoward medical occurrence that at any dose may result in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product.	From Day 29 up to 6 months after study vaccination 2 (up to 7 months)
Number of Participants With Adverse Events of Special Interest (AESI) Up to Study Vaccination 1	Number of participants with AESI up to study vaccination 1 were reported. Thrombosis with thrombocytopenia syndrome (TTS) was considered to be an AESI.	From Day 1 up to Day 29
Number of Participants With Adverse Events of Special Interest (AESI) Up to Study Vaccination 2	Number of participants with AESI up to study vaccination 2 were reported. Thrombosis with thrombocytopenia syndrome (TTS) was considered to be an AESI.	From Day 29 up to 6 months after study vaccination 2 (up to 7 months)
Number of Seroconverted Participants After 28 Days of Administration of Influenza Vaccine	Number of seroconverted participants after 28 days of administration of influenza vaccine (fluzone) were reported. Seroconversion is defined for each of the 4 influenza vaccine strains at 28 days after the administration of a quadrivalent high-dose seasonal influenza vaccine: HI titer greater than or equal to (>=) 1:40 in participants with a pre-vaccination HI titer of less than (<) 1:10, or a >=4-fold HI titer increase in participants with a pre-vaccination HI titer of >=1:10.	28 days after vaccination with fluzone on Day 1 (up to Day 29)
Number of Seroprotected Participants After 28 Days of Administration of Influenza Vaccine	Number of seroprotected participants after 28 days of administration of influenza vaccine (fluzone) were reported. Seroprotection is defined for each of the 4 influenza vaccine strains as HI titer >=1:40 at 28 days after the administration of a quadrivalent high-dose seasonal influenza vaccine.	28 days after vaccination with fluzone on Day 1 (up to Day 29)

Collaborators and Investigators

• Sponsor: Janssen Vaccines & Prevention B.V.
• Investigators: Study Director: Janssen Vaccines & Prevention B.V. Clinical Trial, Janssen Vaccines & Prevention B.V.

Study record dates

Study Major Dates

• Study Start (Actual): October 4, 2021
• Primary Completion (Actual): April 20, 2022
• Study Completion (Actual): October 11, 2022

Study Registration Dates

• First Submitted: September 28, 2021
• First Submitted That Met QC Criteria: September 28, 2021
• First Posted (Actual): October 8, 2021

Study Record Updates

• Last Update Posted (Actual): May 25, 2025
• Last Update Submitted That Met QC Criteria: May 22, 2025
• Last Verified: May 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Respiratory Tract Infections; Infections; Orthomyxoviridae Infections; RNA Virus Infections; Virus Diseases; Respiratory Tract Diseases; Influenza, Human; Immunologic Factors; Physiological Effects of Drugs; Vaccines
• Other Study ID Numbers: CR109064; VAC18193RSV3005 (Other Identifier: Janssen Vaccines & Prevention B.V.)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No